BioCryst Pharmaceuticals | BCRX - 债务



金融业
股票价格
USD
资产
USD 514.16M
现金及等价物
USD 335.91M
销售成本
USD 9.52M
流动资产
USD 404.35M
流动负债
USD 196.07M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -119.15M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 428.67M
市值
USD 1.89B
净收入
USD 245.85M
营业费用
USD 146.17M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.4M
贸易债权人
USD 15.83M
应收帐款人
USD 106.82M


债务 更改 日
Alnylam Pharmaceuticals USD 1.28B 30.06M 2025-12
BioCryst Pharmaceuticals USD 828.6M 510K 2024-12
Chugai Pharma JPY 14.11B 1.93B 2022-12
Daiichi Sankyo JPY 201.14B 99.81B 2025-09
DBV Technologies USD 8.59M 295K 2025-09
Enanta Pharmaceuticals USD 1.35M 0 2024-12
Gilead Sciences USD 24.94B 5M 2025-12
GlaxoSmithKline GBP 19.06B 1.34B 2026-03
Glaxosmithkline GBP 17.75B 396M 2025-09
Incyte USD 39.43M 982K 2026-03
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
Neurocrine Biosciences USD 415.3M 13.1M 2025-12
Novavax USD 233.31M 4.23M 2024-09
PTC Therapeutics USD 2.71B 2.42B 2025-12
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Roche Holding CHF 33.03B 1.41B 2025-06
Sarepta Therapeutics USD 1.25B 103.69M 2025-09
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Vertex Pharmaceuticals USD 2.03B 195.7M 2025-12